[{"id":"6e09028c-351c-49a3-ae4b-ecc4e168b4c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04267120","created_at":"2021-01-18T20:44:00.448Z","updated_at":"2025-02-25T16:10:00.555Z","phase":"Phase 2","brief_title":"Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)","source_id_and_acronym":"NCT04267120","lead_sponsor":"Washington University School of Medicine","biomarkers":" SDHB • TSC1","pipe":" | ","alterations":" TSC1 deletion","tags":["SDHB • TSC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TSC1 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 07/29/2020","start_date":" 07/29/2020","primary_txt":" Primary completion: 07/09/2024","primary_completion_date":" 07/09/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-11-26"}]